stockrowTango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −5.71%
- Free cash flow
- −4.58%
Quarter to June 2026, against a year earlier
Follow TNGX
Alert me
Tango Therapeutics, Inc. (TNGX) Free cash flow
Tango Therapeutics, Inc.'s free cash flow for fiscal 2025 was −$139.9M, compared with −$132.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$144.2M. Over the past ten years it has ranged from −$139.9M (fiscal 2025) to $69.0M (fiscal 2020) — the current reading is the lowest in ten years. Free cash flow has fallen for 5 consecutive fiscal years. Tango Therapeutics, Inc. ranks 495th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$139.9M | — |
| FY2024 | −$132.3M | — |
| FY2023 | −$119.5M | — |
| FY2022 | −$116.8M | — |
| FY2021 | −$61.4M | — |
| FY2020 | $69.0M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$38.8M | — |
| Mar 2026 | −$44.4M | — |
| Dec 2025 | −$29.9M | — |
| Sep 2025 | −$31.1M | — |
| 20 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $82.0M |
| PBLS Parabilis Medicines, Inc. compare | −$119.1M |
| ABCL AbCellera Biologics Inc. compare | −$119.7M |
| TNGX Tango Therapeutics, Inc. | −$144.2M |
| EWTX Edgewise Therapeutics, Inc. compare | −$158.8M |
| IRON Disc Medicine, Inc. compare | −$197.5M |
| RLAY Relay Therapeutics, Inc. compare | −$212.2M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$216.1M |
| XENE Xenon Pharmaceuticals Inc. compare | −$338.5M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on TNGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement